EMBL Ventures

Last activity: 01.06.2024
EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.
Employees: 1-10

News 71

07.05.2024Topas Therapeutics Appoints Hugo Fry as CEO-
27.02.2024Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP-
30.01.2024Allecra Licensor Advanz receives positive CHMP opinion for EXBLIFEP-
27.06.2023Allecra Therapeutics Submits New Drug Application to the U.S. FDA-
05.10.2022Allecra Publishes Final Phase 3 ALLIUM Data in JAMA-
15.02.2022Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer-
13.01.2022Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe-
12.01.2022BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies-
27.07.2021Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million)-
27.07.2021Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round-
Show more

Mentions in press and media 1

14.10.2015Luxendo Closes €6M Series A FinancingLuxendo, a startup launched by the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBLEM Technology Transfer (EMBLEM) in Heidelberg, Germany, closed a €6M Series A financing. The round was co-led by EMBL Ventur...

Reviews 0

Sign up to leave a review

Sign up Log In